Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

TwitteringTom Apr. 10 at 7:30 PM

$CGEN what we thinking about this conference next week? anything of substance going to be said?

1 · Reply

Ghrr Apr. 10 at 4:44 PM

$CGEN Stock will be over $3.00 soon. Would not be surprised to see a buy out offer forthcoming. With positive momentum makes sense that AZ or Gilead buys them outright.

1 · Reply

AGC_Trader Apr. 10 at 3:37 PM

$CGEN exactly 14 months ago it touched $2.66 before dropping down significantly. Let's see what happens now...

0 · Reply

KoalaFlipper Apr. 10 at 3:09 PM

$CGEN Goods news!! Latest Trading Activity (as of close April 9, 2026): Price: The stock closed at $2.48, representing an 8.30% gain on the day. Performance: CGEN has seen a significant surge, with a 7.51% rise in the last week and an 11.71% rise over the past month. It has shown +105.0% price growth over the past year. Volume: Trading volume increased on April 9, with approximately 434,000 shares traded. 52-Week Range: The stock is trading near its 52-week high of $2.49, having recovered from a low of $1.13. Key Drivers & Recent News: AstraZeneca Milestone: Shares rose in premarket trade on April 10, 2026, following a milestone achievement in a cancer program. Profitability & Revenue: The company has reported strong revenue growth, including a significant beat on Q4 2025 earnings, driven by its collaboration with AstraZeneca. Cash Runway: Compugen has extended its cash runway to 2029, bolstered by recent strategic partnerships. Seems like its trending!

0 · Reply

KoalaFlipper Apr. 10 at 3:06 PM

$CGEN 2,60+ coming?

0 · Reply

TwitteringTom Apr. 10 at 2:24 PM

$CGEN

0 · Reply

HuntingBenjmins Apr. 10 at 1:53 PM

$CGEN Saw $2.75 on this last night!

0 · Reply

John_McClane911 Apr. 10 at 10:33 AM

$CGEN = next MEME-STOCK 👀

0 · Reply

focafoca99 Apr. 9 at 7:54 PM

$CGEN is just announcing its presentation and webcast at the virtual Needham conference.

0 · Reply

John_McClane911 Apr. 9 at 6:57 PM

$CGEN If you´re willing to hold long enough you will see 9+. No doubt!

0 · Reply

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Mar 2, 2026, 7:00 AM EST - 5 weeks ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Feb 19, 2026, 7:00 AM EST - 7 weeks ago

Compugen to Participate in Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 7 weeks ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 12, 2026, 7:00 AM EST - 2 months ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Dec 17, 2025, 7:00 AM EST - 4 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Nov 10, 2025, 7:00 AM EST - 5 months ago

Compugen Reports Third Quarter 2025 Results

Nov 4, 2025, 7:00 AM EST - 5 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 6 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 6 months ago

Compugen to Present at SITC 2025

Sep 8, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 9 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 21, 2025, 7:00 AM EDT - 9 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 7:00 AM EDT - 11 months ago

Compugen Reports First Quarter 2025 Results

May 13, 2025, 7:00 AM EDT - 11 months ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 2 years ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 2 years ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Compugen to Participate in Two Upcoming Investor Conferences

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 6, 2024, 7:00 AM EST - 2 years ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

TwitteringTom Apr. 10 at 7:30 PM

$CGEN what we thinking about this conference next week? anything of substance going to be said?

1 · Reply

Ghrr Apr. 10 at 4:44 PM

$CGEN Stock will be over $3.00 soon. Would not be surprised to see a buy out offer forthcoming. With positive momentum makes sense that AZ or Gilead buys them outright.

1 · Reply

AGC_Trader Apr. 10 at 3:37 PM

$CGEN exactly 14 months ago it touched $2.66 before dropping down significantly. Let's see what happens now...

0 · Reply

KoalaFlipper Apr. 10 at 3:09 PM

0 · Reply

KoalaFlipper Apr. 10 at 3:06 PM

$CGEN 2,60+ coming?

0 · Reply

TwitteringTom Apr. 10 at 2:24 PM

$CGEN

0 · Reply

HuntingBenjmins Apr. 10 at 1:53 PM

$CGEN Saw $2.75 on this last night!

0 · Reply

John_McClane911 Apr. 10 at 10:33 AM

$CGEN = next MEME-STOCK 👀

0 · Reply

focafoca99 Apr. 9 at 7:54 PM

$CGEN is just announcing its presentation and webcast at the virtual Needham conference.

0 · Reply

John_McClane911 Apr. 9 at 6:57 PM

$CGEN If you´re willing to hold long enough you will see 9+. No doubt!

0 · Reply

Oscar_66 Apr. 9 at 5:43 PM

$CGEN I'll bite. Hope to not get bitten...

0 · Reply

KoalaFlipper Apr. 9 at 4:38 PM

$CGEN target price 4,00 looks real to me!

0 · Reply

KoalaFlipper Apr. 9 at 4:22 PM

$CGEN still very undervalued

0 · Reply

HuntingBenjmins Apr. 9 at 3:42 PM

$CGEN

0 · Reply

TwitteringTom Apr. 9 at 3:28 PM

$CGEN time

0 · Reply

John_McClane911 Apr. 9 at 2:50 AM

$CGEN

0 · Reply

wenmoon_stonks Apr. 9 at 12:54 AM

$CGEN

0 · Reply

wenmoon_stonks Apr. 9 at 12:53 AM

$CGEN is there some kind of code that says it gets rejected at $2.36 every time? This is ridiculous look at the one-year chart. It is throbbing for a breakout

1 · Reply

TwitteringTom Apr. 8 at 2:32 PM

$CGEN and we are flat LOL

0 · Reply

TwitteringTom Apr. 8 at 2:10 PM

$CGEN ugh we can get more today of all days

0 · Reply

HuntingBenjmins Apr. 8 at 2:06 PM

$CGEN Saw something in the $2.40’s this morning. Been a LONG time since we’ve seen that.

0 · Reply

TwitteringTom Apr. 7 at 7:23 PM

$CGEN go

0 · Reply

Market Cap	234.49M
Revenue (ttm)	72.76M
Net Income (ttm)	35.34M
EPS (ttm)	N/A
PE Ratio	6.19
Forward PE	N/A
Profit Margin	48.57%
Debt to Equity Ratio	0.00

Volume	765,600
Avg Vol	290,254
Day's Range	N/A - N/A
Shares Out	94.55M
Stochastic %K	90%
Beta	2.77
Analysts	Strong Sell
Price Target	$5.83